Aventis: New Drug Application for the Treatment of Viral Respiratory Infection (VRI, or the Common Cold)

Picovir™ (pleconaril) to be Reviewed by FDA Antiviral Drugs Advisory Committee on March 19, 2002

08-Feb-2002

Aventis Pharmaceuticals Exton, PA, and Bridgewater, N.J., February 7, 2002 – ViroPharma Incorporated (Nasdaq: VPHM) and Aventis Pharmaceuticals, the U.S. pharmaceutical company of Aventis Pharma AG, today announced that the new drug application for Picovir™ (pleconaril), an investigational product being developed for the treatment of viral respiratory infection (VRI, or the common cold) in adults, is scheduled to be reviewed by the Antiviral Drugs Advisory Committee of the U.S. food and Drug Administration (FDA) on March 19, 2002.

ViroPharma submitted the new drug application (NDA) for marketing approval of Picovir™ to the FDA in July 2001. In late September 2001, ViroPharma was notified that the Picovir™ NDA submission was accepted for filing; also in September, ViroPharma and Aventis signed an agreement to co-develop and co-promote Picovir™ in the United States.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the commercialization, development and discovery of antiviral pharmaceuticals. ViroPharma is focused on drug development and discovery activities in viral diseases including viral respiratory infection (VRI), hepatitis C and RSV disease. ViroPharma's most advanced product candidate, Picovir™, is in clinical development for the treatment of picornavirus diseases, and is the subject of a new drug application (NDA) that is being reviewed by the U.S. Food and Drug Administration for the treatment of VRI in adults. ViroPharma also has product candidates in preclinical and clinical development for the treatment of hepatitis C and RSV diseases.

https://www.chemeurope.com/en/news/8145/aventis-new-drug-application-for-the-treatment-of-viral-respiratory-infection-vri-or-the-common-cold.html